Thromboxane A2 is Involved in Itch-associated Responses in Mice with Atopic Dermatitis-like Skin Lesions

Andoh, Tsugunobu; Yamamoto, Ai; Haza, Satomi; Yuhki, Koh-ichi; Ushikubi, Fumitaka; Narumiya, Shu; Kuraishi, Yasushi

Acta Dermato Venereologica (2016), 96(7): 899-904

© 2016 The Authors. All articles are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Kyoto University
INVESTIGATIVE REPORT

Thromboxane A₂ is Involved in Itch-associated Responses in Mice with Atopic Dermatitis-like Skin Lesions

Tsugunobu ANDOH¹, Ai YAMAMOTO¹, Satomi HAZA¹, Koh-ichi YUHKI², Fumitaka USHIKUBI², Shu NARUMIYA³ and Yasushi KURAISHI⁴

¹Department of Applied Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, ²Department of Pharmacology, Asahikawa Medical University, Asahikawa, ³Department of Pharmacology, Graduate School of Medicine, Kyoto University, Kyoto, and ⁴Research Administration Division, Tokyo Medical and Dental University, Tokyo, Japan

To investigate the mechanisms underlying itching in atopic dermatitis, we examined whether thromboxane (TX) A₂, an arachidonic acid metabolite, is involved in spontaneous scratching, an itch-related response, in NC mice with atopic dermatitis-like skin lesions. The TXA₂ receptor (TP) antagonist ONO-3708 inhibited the spontaneous scratching. The mRNA expression of TX synthase (TXSyn) distributed mainly in epidermis and the concentration of TXB₂, a metabolite of TXA₂, were increased in lesional skin. Scratching caused by the PAR2 agonist SLIGRL-NH₂ was suppressed by ONO-3708. SLIGRL-NH₂-induced scratching decreased approximately 75% in TP-deficient mice, compared to wild-type mice. In primary cultures of mouse keratinocytes, SLIGRL-NH₂ induced the production of TXA₂ as evidenced by the increased TXB₂, which was inhibited by the TXSyn inhibitor sodium ozagrel and a PAR2-neutralizing antibody. Taken together, these results suggest that epidermal TXA₂, which may be produced via PAR2 activation, is involved in itching in atopic dermatitis. Key words: itch; thromboxane A₂; TP receptor; thromboxane synthase; atopic dermatitis; proteinase-activated receptor 2.

Accepted Apr 6, 2016; Epub ahead of print Apr 12, 2016


Tsugunobu Andoh, Department of Applied Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930-1094, Japan. E-mail: andoht@pha.u-toyama.ac.jp

Atopic dermatitis (AD) is a severe, chronic inflammatory skin disease and itching constitutes its major diagnostic criterion (1–3). In AD patients, scratching induced by the itch sensation aggravates dermatitis and increases the frequency of itching (4). Therefore, itch control is very important for improving quality of life and treating AD. Although H₁ histamine receptor antagonists often serve as the drug of first choice for treating itching, AD-derived itching responds poorly to these drugs (5), suggesting that histamine is not essential for AD itching. Therefore, a comprehensive understanding of the mechanisms and mediators underlying AD itching is limited.

Glucocorticoids attenuate itching in chronic skin diseases including AD (6–8). The mechanisms underlying the pharmacological action of glucocorticoids including the inhibition of phospholipase A₂ (9) and the regulation of the expression of cyclooxygenase (COX)-2, but not COX-1 (10), have been elucidated. These findings suggest that arachidonic acid metabolites, which are regulated by glucocorticoids, are involved in the itch sensation.

Thromboxane (TX) A₂ is an arachidonic acid metabolite produced by catalysis with COX and TX synthase (TXSyn) and is altered spontaneously to form inactive TXB₂. Additionally, TXA₂ exerts its pharmacological activity (e.g., platelet aggregation) via the thromboxane TXA₂ receptor (TP), a G-protein coupled receptor (11) also involved in allergic skin inflammation (12). In patients with pruritic diseases, the serum concentration of TXB₂, a metabolite (and therefore an indicator) of TXA₂, is increased (13–16). Moreover, intradermal injection of TXA₂ elicits scratching, an itch-associated response, in mice (17). These results suggest that TXA₂ plays an important role in the itching sensation that accompanies several pruritic skin diseases. However, it remains unclear whether TXA₂ is involved in AD-associated itching.

NC mice that are maintained for a long time in a conventional environment develop chronic dermatitis, hyperplasia, dry skin, increased serum IgE levels, mast cells in the skin and spontaneous scratching, an itch-related behavior (18, 19); these features are similar to those of AD patients (1–3). In this study, we investigated whether TXA₂ is involved in spontaneous itching in NC mice with AD-like chronic dermatitis.

MATERIALS AND METHODS

Animals

Male NC/Nga mice (14–21 weeks old), purchased from Japan SLC (Hamamatsu, Japan), were used in this study. The mice were bred in a specific pathogen-free environment at the Division of Animal Resource and Development, Life Science Research Center, University of Toyama, and in a conventional environment in the experimental animal room in the Department of Applied Pharmacology, University of Toyama. All mice, except for the healthy controls, were kept together with mite-infected mice with chronic dermatitis for 2 weeks at 4–5 weeks of age in a conventional environment in the experimental animal
Agents (see Appendix S1)

Primary cultures of mouse keratinocytes (see Appendix S1)

Behavioral experiments (see Appendix S1)

Real-time PCR (see Appendix S1)

Reverse transcription and PCR (see Appendix S1)

Enzyme immunoassay for TXB₂

Animals were anesthetized with sodium pentobarbital (80 mg/kg) and transcardially perfused with phosphate-buffered saline (PBS). The skin was isolated using an 8-mm-diameter punch, immediately shredded with scissors, and added to 1 ml of ice-chilled ethanol containing 10 μM indomethacin and 10 μM zileuton to inhibit cyclooxygenase and 5-lipoxygenase, respectively. Following homogenization, each sample was centrifuged at 600 × g at 4°C for 10 min. The supernatant (0.8 ml) was mixed with 5 ml of distilled water (pH 3.0) and applied to a 50-μl Sep-Pak cartridge (Waters, Milford, MA, USA) equilibrated with methanol. The cartridges were washed with hexane followed by distilled water and the lipids were then eluted with methyl formate. The eluted fraction was then evaporated and the resulting residue was suspended in an enzyme immunoassay buffer (Cayman Chemical, Ann Arbor, MI, USA) for the assay of TXB₂. The amount of TXB₂ was determined using an enzyme immunoassay kit (Cayman Chemical). In the case of cultured keratinocytes, the culture medium was changed to mouse keratinocyte growth medium (CatPrime basal medium; CELLnTEC Advanced Cell Systems AG), as the assay medium. Samples for the assay of TxB₂ were obtained from the supernatant 5 min post SLIGRL-NH₂ administration. Following collection of culture medium, the cultured keratinocytes were treated with 1% Triton X-100 to solubilize the cell proteins. Total protein concentration was determined using a Bio-Rad Protein Assay Kit (Hercules, CA, USA) and TXB₂ concentration was measured using an enzyme immunoassay kit (Cayman Chemical). The concentration of TXB₂ in keratinocytes was normalized to a skin section (8-mm diameter) and total protein concentration, respectively.

Immunostaining

Under anesthesia with sodium pentobarbital (80 mg/kg, intraperitoneal), the animals were transcardially perfused with PBS following by 4% paraformaldehyde (PFA). The skin of the rostral back was isolated, post-fixed with 4% PFA and then immersed in 30% sucrose solution for 2 days. The tissue was then embedded in Tissue-Tek1 O.C.T. Compound (Sakura Finetek Co., Ltd., Tokyo, Japan) and the frozen samples were sectioned at 16 μm with a cryostat (Leica, Wetzlar, Germany). The sections were washed with PBS and then treated with Protein Block® (DAKO Co., Hamburg, Germany) followed by 0.3% Triton X-100 in PBS. The sections were treated with anti-TXSyn antibody (Cayman Chemical) at 4°C overnight. For some experiments, sections were treated with the antibody (Cayman Chemical) pre-incubated with its specific antigen prior to staining. Subsequent to washing with PBS, the preparations were incubated with Alexa Fluor 488-conjugated anti-rabbit IgG (Life Technologies, Carlsbad, CA, USA) for 1 h at room temperature. Fluorescence signals were observed using a fluorescence microscope (BX-61/DP70, Olympus, Tokyo, Japan). Fluorescent intensity was analyzed with NIH Image software (National Institute of Health, Bethesda, MD, USA).

Statistical analysis

Data are presented as mean ± S.E.M. The statistical significance of differences between group means was analyzed using the Student’s t-test (two groups) or one-way analysis of variance (ANOVA) followed by a post-hoc Holm–Šidák test (3 or more groups). A p-value <0.05 was considered statistically significant.

RESULTS

Spontaneous scratching in NC mice with chronic dermatitis

Fig. 1A shows the number of spontaneous bouts of hind paw scratching towards any region of the body in individual healthy and chronic dermatitis NC mice. Although the healthy mice did not exhibit spontaneous scratching, most age-matched chronic dermatitis mice exhibited apparent spontaneous scratching. In the following experiments, we used healthy NC mice that were given intradermal injections of SLIGRL-NH₂. In other experiments, healthy and chronic dermatitis NC mice were compared.
Effects of TP antagonist on spontaneous scratching in NC mice with chronic dermatitis

The TP receptor antagonist ONO-3708 (30 or 100 mg/kg) significantly inhibited spontaneous scratching in NC mice with chronic dermatitis, compared with the vehicle-treated group (Fig. 1B).

Effects of the TP receptor antagonist and TP receptor-deficiency on SLIGRL-NH$_2$-induced scratching

PAR2 is involved in spontaneous scratching in NC mice with chronic dermatitis (24). Intradermal injection of SLIGRL-NH$_2$ (100 nmol/site), a PAR2 agonist peptide, elicited scratching in healthy NC mice (Fig. 2). ONO-3708 (30 and 100 mg/kg) significantly inhibited scratching induced by SLIGRL-NH$_2$ compared with the vehicle-treated group (Fig. 2 A). While SLIGRL-NH$_2$ (100 nmol/site) induced scratching in wild-type mice, the scratching was decreased by approximately 75% in TP-deficient mice, compared with that in wild-type mice (Fig. 2B). The mRNA expressions of TP receptor, TXSyn and PAR2 in the skin and DRG in wild-type and TP-deficient mice are shown in Fig. S11.

Expression of TXSyn mRNA and TXB$_2$ concentration in NC mouse skin

The expression of TXSyn mRNA (Fig. 3A) and TXB$_2$, a stable degradation product of TXA2 (Fig. 3B), were significantly higher in the lesional skin of NC mice with chronic dermatitis than in the skin of healthy NC mice.

Distribution of TXSyn in the skin of NC mice

In contrast to healthy skin, the lesional skin of NC mice with chronic dermatitis exhibited epidermal hyperplasia (Fig. 4). Immunohistochemical staining and fluorescent
intensity analysis in the epidermis and dermis revealed that TXSyn is predominantly expressed in epidermal keratinocytes (Fig. 4). Staining was eliminated when pre-absorbed antibody was used (Fig. 4 bottom).

The production of \( \text{TXA}_2 \) induced by SLIGRL-NH\(_2\) in primary cultures of mouse keratinocytes

Both TXSyn and PAR2 mRNA were expressed in primary cultures of mouse keratinocytes (Fig. 5A).

SLIGRL-NH\(_2\) (20–200 \( \mu \)M) induced \( \text{TXA}_2 \) production, as determined by an increase in TXB\(_2\) concentration in primary cultures of mouse keratinocytes (Fig. 5B). SLIGRL-NH\(_2\)-induced \( \text{TXA}_2 \) production was significantly inhibited by the TXSyn inhibitor sodium ozagrel (1–10 \( \mu \)M) (Fig. 5B). In addition, the PAR2-neutralized antibody (Fig. S2) also attenuated the \( \text{TXA}_2 \) production inhibited by SLIGRL-NH\(_2\) (Fig. 5C).

DISCUSSION

Responses to pruritogens differ among mouse species (25). An intradermal injection of histamine (10–1,000 nmol/site) did not induce scratching in healthy NC mice (Fig. S3), suggesting that NC mice respond minimally to histamine. Thus, pruritogens other than histamine are involved in the observed spontaneous scratching in NC mice with chronic dermatitis. The results of the present study show that the TP receptor antagonist ONO-3708 inhibits spontaneous scratching in NC mice with chronic dermatitis. In healthy NC mice, an intradermal injection of the \( \text{TXA}_2 \) analogue U-46619 (1–100 nmol/site) elicited dose-dependent scratching (Fig. S3). Additionally, U-46619-induced scratching was inhibited by ONO-3708 (Fig. S4). ONO-3708 inhibits receptor binding of U-46619 but not TXB\(_2\), leukotriene D\(_4\), or prostaglandin D\(_2\) and E\(_1\) (21, 22), suggesting that the action of U-46619 is mediated via the TP receptor. Both TXSyn mRNA expression and \( \text{TXA}_2 \) production, as gauged by TXB\(_2\) concentration, were increased in the skin of NC mice with chronic dermatitis. These results suggest that \( \text{TXA}_2 \) and its receptor are involved in spontaneous itching in NC mice with chronic dermatitis.

TXSyn is a key enzyme involved in the synthesis of \( \text{TXA}_2 \) from prostaglandin H\(_2\), a metabolite of arachidonic acid (26). TXSyn was predominately expressed in epidermal keratinocytes in the skin of both healthy and dermatitis NC mice. Previously, we have also shown that keratinocytes express TXSyn in ICR mice, which are untreated healthy mice (17). Mast cells in the skin also express TXSyn and produce \( \text{TXA}_2 \), as gauged by TXB\(_2\) concentration, were increased in the skin of NC mice with chronic dermatitis. These results suggest that \( \text{TXA}_2 \) and its receptor are involved in spontaneous itching in NC mice with chronic dermatitis.

In the skin of NC mice with chronic dermatitis, expression of TXSyn mRNA was increased. The AP-1
family of transcription factors plays an important role in the promoter activity for TXSyn (28). Increased immunoreactivity to AP-1-related transcription factors (e.g., Jun D, c-Fos, Fos B, Fra-1, and Fra-2) has been observed in the epidermis (29) of AD patients compared to that of healthy subjects. Jun D and c-Fos, in particular, exhibit strong cytoplasmic positivity in the epidermis of AD patients (29). Thus, the increase in AP-1 expression may be related to the elevated TXSyn expression in atopic dermatitis-like skin lesions.

The mechanisms underlying TXA₂ production in lesional skin are not completely understood. Previously, we have demonstrated that serine proteinase and PAR2 are involved in itch-related responses in NC mice with chronic dermatitis (24). In this study, the PAR2 agonist peptide SLIGRL-NH₂-induced itch-related responses were inhibited by a TP receptor antagonist in healthy NC mice and were decreased in TP receptor-deficient mice, suggesting that TXA₂ is involved in PAR2-related responses. PAR2 is predominately expressed in epidermal keratinocytes (24). In primary cultures of NC mouse keratinocytes, the application of a PAR2 agonist peptide induced the production of TXA₂, and this response was inhibited by the TX inhibitor and the PAR2-neutralizing antibody. Thus, PAR2 activation may be involved in the production of TXA₂ in keratinocytes. PAR2 is activated by trypsin-like serine proteinases (e.g., tryptase and kallikrein 5) and a synthetic PAR2-tethered ligand known as PAR2 agonist peptide (30–32). In NC mice with chronic dermatitis, tryptase from mast cells (24) and kallikrein 5 from keratinocytes (33) are involved in itching behavior, suggesting that these serine proteinases play an important role in the production of TXA₂. There are at least two possible pathways by which keratinocytes produce TXA₂ following PAR2 stimulation. PAR2 is a G-protein-coupled receptor (30) and its activation increases the level of free intracellular Ca²⁺ ions (30, 34, 35). Thus, the activation of phospholipase A₂ via increased free intracellular Ca²⁺ ions (36) may promote TXA₂ production. Production may also occur via Rho kinase-mediated phospholipase A₂ activation (37); the activation of PAR2 stimulates Rho kinase activity (38). In addition to the increase in TXSyn expression, these two pathways may contribute to the production of TXA₂ in the lesional skin of NC mice with chronic dermatitis.

In the skin, TP receptors are predominantly expressed in keratinocytes and primary afferent neurons (17) (Fig. S3). In addition, TP receptors are expressed in small-size neurons in the dorsal root ganglion (17); these have chiefly unmyelinated C-fibers (39, 40), which play an important role in itch signaling (41, 42). The application of the TXA₂ analogue U-46619 increases the concentration of free intracellular Ca²⁺ ions, which is inhibited by the TP receptor antagonist, in primary cultures of dorsal root ganglion neurons (17). The action of U-46619 is also inhibited by L-type calcium channel blockers, suggesting that the activation of TP receptors elicits membrane depolarization (43). These observations suggest that TXA₂ acts on primary afferent neurons or through both autocrine and paracrine mechanisms in keratinocytes. Additionally, intra-epidermal neurites increase in the skin of NC mice with chronic dermatitis (44) and patients with atopic dermatitis (45, 46). These findings also support the hypothesis that TXA₂ released from keratinocytes acts directly on primary afferent neurons.

In conclusion, we demonstrated that TXA₂ produced by epidermal keratinocytes is involved in spontaneous itch-related behavior in NC mice with AD-like skin lesions. Moreover, we found that the serine protease-PAR2 system partially contributes to the production of TXA₂. PAR2, TXSyn and TP receptor may constitute potential new targets for the development of antipruritic drugs for AD.

ACKNOWLEDGMENTS

We are very grateful to Ono Pharmaceutical Co. Ltd. for providing the gift of ONO-3708. This study was supported in part by Japan Agency for Medical Research and Development.

The authors declare no conflicts of interest.

REFERENCES
